Table 1.
Patient characteristics of 80 NSCLC patients with LM
| Variable | N (%) |
|---|---|
| Total | 80 (100.0) |
| Gender | |
| Male | 44 (54.1) |
| Female | 36 (45.9) |
| Age, years | |
| Median (range) | 53.5 (30–78) |
| Histology | |
| Adenocarcinoma | 73 (91.3) |
| Squamous | 7 (8.8) |
| Initial stage | |
| I-III | 25 (31.3) |
| IV | 55 (68.8) |
| Previous lines of systematic therapy | |
| 0 | 19 (23.8) |
| 1 | 29 (36.3) |
| 2 | 19 (23.8) |
| ≥ 3 | 13 (16.3) |
| Previous EGFR TKI prior to LM | 46 (57.5) |
| EGFR mutation | |
| EGFR 19del | 25 (31.3) |
| EGFR L858R | 18 (22.5) |
| EGFR T790M | 5 (6.3) |
| EGFR 20INS | 1 (1.3) |
| Wild-type | 31 (38.8) |
Abbreviations: EGFR Epidermal growth factor receptor, TKI Tyrosine kinase inhibitors, LM Leptomeningeal metastasis